ストックスクリーナーアプリを入手
3.67
13.98%
0.45
前日終値:
$3.22
開ける：
$3.27
24時間の取引高:
108.08K
Relative Volume:
1.64
時価総額：
$23.67M
収益：
$5.75M
当期純損益:
$-38.96M
株価収益率:
-0.2943
EPS:
-12.47
ネットキャッシュフロー:
$-32.63M
1週間 パフォーマンス:
+7.31%
1か月 パフォーマンス:
+5.76%
6か月 パフォーマンス:
-45.22%
1年 パフォーマンス:
-45.47%
1日の値動き範囲:
$3.27
$3.8529
1週間の範囲:
$3.159
$3.8529
52週間の値動き範囲:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
KALA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.67 | 22.07M | 5.75M | -38.96M | -32.63M | -12.47 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-14 | ダウングレード | Jefferies | Buy → Hold |
| 2020-07-23 | 開始されました | Northland Capital | Outperform |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-09 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 開始されました | Jefferies | Buy |
すべてを表示
Kala Bio Inc (KALA) 最新ニュース
KALA BIO: Q1 Earnings Snapshot - New Haven Register
KALA Focuses on Advancing KPI-012 Development Amid Pivotal Trials | KALA Stock News - GuruFocus
Kala Pharmaceuticals reports Q1 EPS ($1.41) vs ($4.20) last year - TipRanks
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
KALA's PCED Drug Could Reach 100,000 PatientsQ3 Trial Results Coming - Stock Titan
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Equities Analysts Issue Forecasts for Cryoport Q2 Earnings - Defense World
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Q2 EPS Estimate for Cogent Biosciences Lifted by Analyst - Defense World
Q2 EPS Estimates for Core Scientific Lifted by HC Wainwright - Defense World
KALA BIO (KALA) Projected to Post Quarterly Earnings on Tuesday - Defense World
Q2 Earnings Forecast for Cryoport Issued By Leerink Partnrs - Defense World
KALA BIO (KALA) Projected to Post Earnings on Tuesday - Defense World
Fluence Energy, Inc. (NASDAQ:FLNC) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Sells 5,772 Shares of Turning Point Brands, Inc. (NYSE:TPB) - Defense World
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $426,000 Stake in Sidus Space, Inc. (NASDAQ:SIDU) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Boosts Holdings in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $403,000 Stake in Mobix Labs, Inc. (NASDAQ:MOBX) - Defense World
Wix.com Ltd [WIX] Insider Activity: An Update for Investors - knoxdaily.com
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
Recent Insider Activity Could Benefit Insperity Inc (NSP) - knoxdaily.com
Analyzing Kala Bio Inc (KALA) After Recent Trading Activity - knoxdaily.com
International Business Machines Corp [IBM] Stock sold by Insider Thomas Robert David for $6.72 million - knoxdaily.com
Aurora Cannabis Inc [ACB] Investment Guide: What You Need to Know - knoxdaily.com
Insider Sale Alert: Angi Inc [ANGI] – Is it Time to sell? - knoxdaily.com
Kala Bio Inc (KALA) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Kala Bio Inc (KALA) Stock: A Year of Market Fluctuations - investchronicle.com
Piper Sandler gives a Neutral recommendation for RxSight Inc (RXST) - knoxdaily.com
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Dynatrace, Inc. (NYSE:DT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
Kala Bio Inc (KALA) 財務データ
収益
当期純利益
現金流量
EPS
Kala Bio Inc (KALA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):